European Meeting on HIV & Hepatitis 2019

Andrea De Luca Lecture: The top 10 important observations of the last year affecting clinical management- Ravindra Gupta, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

How does the reservoir influence the clinician's decisions- Carlo Federico Perno, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Genetic Barrier – Clinical Cases- Roger Paredes, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

New approaches to STI management- Gary Whitlock, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

European surveillance of HIV drug resistance to NRTI, NNRTI and INSTI in newly diagnosed individuals using next-generation sequencing - Carole Seguin-Devaux

Slideset

HIV

Viral Hepatitis and Liver Disease

First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain - Manuel Reiriz Rojas

Slideset

HIV

Viral Hepatitis and Liver Disease

Seminal HIV-1 RNA and drug concentrations in DTG+3TC dual therapy (ANRS167 Lamidol)- Charlotte Charpentier

Slideset

HIV

Viral Hepatitis and Liver Disease

Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study- Barbara Rossetti

Slideset

HIV

Viral Hepatitis and Liver Disease

Molecular analysis suggests post-migration HIV-1 acquisition among migrants in Paris, France - Evangelia Kostaki

Slideset

HIV

Viral Hepatitis and Liver Disease

High prevalence of the integrase resistance associated accessory mutation L74I in the Russian Federation- Alina Kirichenko

Slideset

HIV

Viral Hepatitis and Liver Disease

Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy - Anne-Geneviéve Marcelin

Slideset

HIV

Viral Hepatitis and Liver Disease

Presentations from scientists from the industry- Luisa Stamm, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

First line therapies: implications for long term resistance - Anne-Geneviève Marcelin, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Clinical case- Rocio Montejano Sanchez, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Specific NS5A polymorphisms correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b - Mohammad Altkhatib

Slideset

HIV

Viral Hepatitis and Liver Disease

Viral Dynamics During Suppressive ART - Towards HIV-1 Elimination From Reservoirs - Thomas Klimkait

Slideset

HIV

Viral Hepatitis and Liver Disease

European Meeting on HIV & Hepatitis 2019

Andrea De Luca Lecture: The top 10 important observations of the last year affecting clinical management- Ravindra Gupta, MD, PhD

How does the reservoir influence the clinician's decisions- Carlo Federico Perno, MD, PhD

Genetic Barrier – Clinical Cases- Roger Paredes, MD, PhD

New approaches to STI management- Gary Whitlock, MD

European surveillance of HIV drug resistance to NRTI, NNRTI and INSTI in newly diagnosed individuals using next-generation sequencing - Carole Seguin-Devaux

First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain - Manuel Reiriz Rojas

Seminal HIV-1 RNA and drug concentrations in DTG+3TC dual therapy (ANRS167 Lamidol)- Charlotte Charpentier

Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study- Barbara Rossetti

Molecular analysis suggests post-migration HIV-1 acquisition among migrants in Paris, France - Evangelia Kostaki

High prevalence of the integrase resistance associated accessory mutation L74I in the Russian Federation- Alina Kirichenko

Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy - Anne-Geneviéve Marcelin

Presentations from scientists from the industry- Luisa Stamm, MD, PhD

First line therapies: implications for long term resistance - Anne-Geneviève Marcelin, MD

Clinical case- Rocio Montejano Sanchez, MD

Specific NS5A polymorphisms correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b - Mohammad Altkhatib

Novel markers on HBV / HDV co-infection - Valentina Svicher, PhD

The new patient - with what & when - Peter Reiss, MD, PhD

The aging patient - Eugenia Negredo, PhD

Longitudinal analysis of proviral HIV-DNA - Eva Heger

Single genome sequencing of near full-length HIV-1 RNA - Laura Hebberecht

Maraviroc as a Latency Reversing Agent in cell line models - Filippo Dragoni

Update on the London patient - Ravindra Gupta, MD, PhD

Viral Dynamics During Suppressive ART - Towards HIV-1 Elimination From Reservoirs - Thomas Klimkait

Perspectives in HBV cure research - Fabien Zoulim, MD, PhD